CD8A and neoplasm: Our findings suggest that TNBCvax effectively inhibited the development of mammary tumors by multi-epitope-specific Th1 immunity, enhances CD8+ T cell–mediated cytotoxic responses, and fosters central memory T cell formation, leading to improved tumor control without significant toxicity.